VC-backed Revance Therapeutics files for IPO – Fortune

Fortune has reported that Revance Therapeutics has filed for an $86.25 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol “RVNC.” Cowen & Co. and Piper Jaffray will serve as lead underwriters. Based in Newark, California, Revance is a biopharmaceutical company that is providing solutions for the way drugs are delivered. Its backers include Essex Woodlands Health Ventures, NovaQuest Capita, Technology Partners, Vivo Ventures, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corp.

Related Posts

Leave a Reply

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups